SHARE

FEATURED STORY December 28, 2022

Welcome (But Last Minute) Relief for Prescription Drug Reporting Originally Due December 27

You've Reached Your
Free Article Limit This Month
Register for free to get unlimited access to all Law.com OnPractice content.
Register Now

Section 204 of Title II of Division BB of the Consolidated Appropriations Act, 2021 amended the Internal Revenue Code, the Employee Retirement Income Security Act of 1974 and the Public Health Service Act to add rules governing prescription drug data collection (RxDC). The rules require group health plans, including plans offered to Federal Employees Health Benefits carriers, and health insurance issuers to report certain information related to prescription drug and other healthcare expenditures to the US Departments of Labor, Health and Human Services and the Treasury (collectively, the Departments). Under the statute, the first RxDC reports were due to be filed by December 27, 2021. However, in response to concerns expressed by stakeholders, enforcement was pushed back a full year to December 27, 2022.

IN DEPTH


In an FAQ issued December 23, 2022 (FAQ About Affordable Care Act and Consolidated Appropriations Act, 2021 Implementation Part 56), the Departments provided relief to group health plans and health insurance issuers who are required to report information relating to prescription drug and healthcare spending.

According to the FAQ, "plans and issuers may encounter significant operational challenges" in complying with the RxDC requirements. The FAQ further recognizes that the need to coordinate submission of a plan or issuer's data across multiple reporting entities—and to accurately classify, compile and validate the required data—will likely result in "errors or other issues [ ] despite good faith efforts by plans and issuers." The FAQ advises that the Departments will not take enforcement action against any plan or issuer that makes a good faith effort to comply and establishes a submission grace period through January 31, 2023.

The FAQ also provides further "clarifications" to the RxDC rules, including:

  • Multiple Submissions by the Same Reporting Entity Is Allowed. To prevent unnecessary duplication, the RxDC rules generally bar multiple submissions of the same data file. However, the FAQ waives this requirement. Reporting entities may now create more than one submission for the year, instead of including the data of all clients within a single set of plan lists and data files for the year.
  • Submissions by Multiple Reporting Entities Is Allowed. More than one reporting entity may submit the same data file type on behalf of the same plan or issuer, instead of working together to consolidate all of the plan or issuer's data into a single data file for each type of data.
  • Aggregation Restriction Is Suspended. The RxDC rules require that reporting entities submitting the required data on behalf of one or more plans or issuers must be aggregated to at least the aggregation level used by the reporting entity that submits data on the total annual spending on healthcare services on behalf of those plans or issuers. This requirement is waived for 2020 and 2021 data only.
  • Submission of Premium and Life-Years Data by Email Is Available for Certain Group Health Plans. Email submissions are permitted where the reporting entity is only submitting plan lists, premium and life-years data and the narrative response (if no other data is submitted).
  • Reporting on Vaccines Is Optional. Reporting entities may—but are not required to—incorporate certain vaccines in their data files.
  • Reporting Amounts Not Applied to the Deductible or Out-of-Pocket Maximum Are Optional. Reporting entities do not have to report a value for "Amounts not applied to the deductible or out-of-pocket maximum" and the "Rx Amounts not applied to the deductible or out-of-pocket maximum."

The relief provided by the FAQ is limited. The RxDC rules require the collection and organization of voluminous amounts of data from disparate sources and for different purposes, and reporting sometimes requires a heretofore unheard-of level of vendor-to-vendor cooperation. While a longer good faith compliance period might be more helpful particularly for group health plan sponsors, the FAQ is still very much welcome.

ALM expressly disclaims any express or implied warranty regarding the OnPractice Content, including any implied warranty that the OnPractice Content is accurate, has been corrected or is otherwise free from errors.

More From McDermott Will & Emery

Trending in Telehealth: January 9 - 16, 2023

By Amanda Enyeart McDermott Will & Emery January 19 , 2023

Trending in Telehealth is a new weekly series from the McDermott Digital Health team where we track telehealth regulatory and legislative activity.

That Stings: Consent to Jurisdiction Must Be Effective at Filing to Invoke Fed. R. Civ. P. 4(k)(2)

By Joshua Revilla McDermott Will & Emery January 19 , 2023

The US Court of Appeals for the Federal Circuit, on petition for writ of mandamus, vacated the district court’s transfer order and remanded the transfer to be considered under the clarified parameters of Fed. R. Civ. P. 4(k)(2) and 28 U.S.C. § 1404.

Absent Expressed Rationale of Obviousness, Federal Circuit Calls for Do-Over

By Anisa Noorassa McDermott Will & Emery January 19 , 2023

The US Court of Appeals for the Federal Circuit reversed a ruling by the Patent Trial & Appeal Board (Board) where, on appeal, the US Patent & Trademark Office’s (PTO) rationale for sustaining the Board’s obviousness rejection did not reflect “the reasoning or findings the Board actually invoked.”

More From Health Care

5 Trends to Watch 2023: Health Care & FDA

By Nancy E. Taylor Greenberg Traurig January 23 , 2023

Since its inception in 2006, the private plan alternative to traditional Medicare now covers nearly 48% of the entire country’s Medicare population—about 28.4 million Medicare beneficiaries nationwide.

U.S. Supreme Court Dismisses as 'Improvidently Granted' Case on Scope of Attorney-Client Privilege

By Stephanie L. Adler-Paindiris Jackson Lewis P.C. January 23 , 2023

In a per curiam opinion, the U.S. Supreme Court has dismissed the writ of certiorari granted in In re: Grand Jury, No. 21-1397, writing only that it was “improvidently granted.”

Cookies and Other Tracking Technologies May Violate HIPAA

By Karin E. Ross Greenberg Traurig January 18 , 2023

In the midst of significant privacy changes in many U.S. states affecting tracking technologies such as cookies, pixels, and adtech, new lawsuits are alleging entities violated the Health Insurance Portability and Accountability Act of 1996 (HIPAA) via impermissible disclosure of protected health information due to the use of these technologies.

Featured Stories
Closeclose
Search
Menu

Working...